FibroBiologics, Inc. financial data

Symbol
FBLG on Nasdaq
Location
Houston, TX
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 24 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 112% % 29%
Debt-to-equity 360% %
Return On Equity -786% % -114%
Return On Assets -171% % -81%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 67,594,722 shares 79%
Entity Public Float $21,600,000 USD -85%
Common Stock, Value, Issued $1,000 USD
Weighted Average Number of Shares Outstanding, Basic 44,660,518 shares 36%
Weighted Average Number of Shares Outstanding, Diluted 44,660,518 shares 36%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $7,407,000 USD 64%
General and Administrative Expense $9,242,000 USD 0.1%
Operating Income (Loss) $16,649,000 USD -21%
Nonoperating Income (Expense) $740,000 USD -126%
Net Income (Loss) Attributable to Parent $18,646,000 USD -67%
Earnings Per Share, Basic -0.42 USD/shares -24%
Earnings Per Share, Diluted -0.42 USD/shares -24%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,894,000 USD -65%
Other Assets, Current $0 USD -100%
Assets, Current $6,349,000 USD -55%
Property, Plant and Equipment, Net $842,000 USD 2.2%
Operating Lease, Right-of-Use Asset $2,380,000 USD 71%
Assets $9,619,000 USD -42%
Contract with Customer, Liability, Current $241,000 USD
Liabilities, Current $1,759,000 USD -86%
Operating Lease, Liability, Noncurrent $1,704,000 USD 73%
Liabilities $3,463,000 USD -75%
Retained Earnings (Accumulated Deficit) $54,164,000 USD -52%
Stockholders' Equity Attributable to Parent $6,156,000 USD 125%
Liabilities and Equity $9,619,000 USD -42%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $5,275,000 USD -23%
Net Cash Provided by (Used in) Investing Activities $43,000 USD -438%
Common Stock, Shares Authorized 300,000,000 shares 200%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,318,000 USD -429%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,894,000 USD -65%
Deferred Tax Assets, Valuation Allowance $9,232,000 USD 76%
Deferred Tax Assets, Gross $9,744,000 USD 72%
Operating Lease, Liability $2,410,000 USD 74%
Depreciation $244,000 USD 55%
Payments to Acquire Property, Plant, and Equipment $43,000 USD 438%
Lessee, Operating Lease, Liability, to be Paid $2,728,000 USD 77%
Property, Plant and Equipment, Gross $1,290,000 USD 25%
Operating Lease, Liability, Current $706,000 USD 76%
Lessee, Operating Lease, Liability, to be Paid, Year Two $849,000 USD 56%
Lessee, Operating Lease, Liability, to be Paid, Year One $845,000 USD 74%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $318,000 USD 105%
Lessee, Operating Lease, Liability, to be Paid, Year Three $347,000 USD -32%
Deferred Tax Assets, Operating Loss Carryforwards $7,483,000 USD 107%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $355,000 USD
Additional Paid in Capital $60,319,000 USD 58%
Deferred Tax Assets, Net of Valuation Allowance $512,000 USD 22%
Share-based Payment Arrangement, Expense $2,686,000 USD 21%
Interest Expense $200,000 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%